Home > Haematology > EHA 2019 > Myeloid Malignancies > Initial data on AMV564 in patients with relapsed/refractory AML

Initial data on AMV564 in patients with relapsed/refractory AML

Prof. Gail Roboz, Weill Cornell Medicine, USA
EHA 2019
Phase 1, AMV564-101

AMV564-101 is a phase 1, first-in-human, dose escalation and dose expansion trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AMV564 in patients with relapsed or refractory acute myeloid leukaemia (AML) after 1-2 prior induction regimens (with a standard anthracycline-based regimen or hypomethylating agent) and no more than 2 prior salvage regimens. Prof. Gail Roboz (Weill Cornell Medicine, USA) highlighted initial data from the dose-escalation portion of data from 33 patients treated within 9 cohorts, demonstrating favourable safety profile and initial efficacy data that AMV564 is active [1].

AMV564 is a bivalent, bispecific CD33/CD3 T cell engager with 2 binding sites for CD3 (expressed on T cells) and 2 binding sites for CD33 (highly expressed in myeloid-derived suppressor cells and on >95% of AML blasts). AMV564 brings T c...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on